May 21, 2024 1:19 pm
Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Set for April 2, 2024

Adaptive Biotechnologies Corporation, based in Seattle and listed on Nasdaq as ADPT, is a biotechnology company that focuses on leveraging the genetics of the adaptive immune system for clinical products. These products aim to diagnose and treat diseases, including cancer, autoimmune disorders, and infectious diseases. The company’s immune medicine platform is designed to decode and utilize the complexities of the adaptive immune system with speed, precision, and scale.

In order to provide investors with an update on their progress and future plans, Adaptive Biotechnologies will be hosting a business update conference call and webcast on April 2, 2024. This event will take place after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. It will be accessible through the “Investors” section of their website at www.adaptivebiotech.com and will be archived for replay within 24 hours.

Adaptive Biotechnologies believes that the adaptive immune system has great potential for diagnosing and treating diseases but its complexity has limited its full utilization. They are working to change this by developing clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products focus on diagnosing, monitoring, and treating diseases with personalized immune-driven clinical products for each patient.

For media inquiries, the Associate Director of Corporate Communications, Erica Jones can be contacted at 206-279-2423 or [media@adaptivebiotech.com](mailto:media@adaptivebiotech.com). Investors interested in learning more about Adaptive Biotechnologies can reach out to Vice President of Investor Relations Karina Calzadilla at 201-396-1687 or [investors@adaptivebiotech

Leave a Reply